home / stock / xncr / xncr news

XNCR News and Press, Xencor Inc. From 05/05/22

Stock Information
Company Name: Xencor Inc.
Stock Symbol: XNCR
Market: NASDAQ
Website: xencor.com
Menu
XNCR XNCR Quote XNCR Short XNCR News XNCR Articles XNCR Message Board
Get XNCR Alerts

News, Short Squeeze, Breakout and More Instantly...
XNCR - Xencor Reports First Quarter 2022 Financial Results

-- Management to Host Conference Call at 4:30 p.m. ET Today -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported financial results for the firs...
XNCR - Xencor to Host First Quarter 2022 Financial Results Webcast and Conference Call on May 5, 2022

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that it will release first quarter 2022 financial results after the market closes on Thursday, May ...

XNCR - Xencor Presents Data from Multiple Preclinical XmAb® Cytokine Programs at the American Association for Cancer Research (AACR) Annual Meeting 2022

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the presentation of new data from its preclinical-stage IL-18 and LAG3-targeted IL-15 cytokine prog...

XNCR - Xencor to Present Preclinical Data from XmAb® Cytokine Programs at the American Association for Cancer Research (AACR) Annual Meeting 2022

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will present preclinical data on two novel XmAb ® cytokine programs at the American Ass...
XNCR - Xencor, Inc. (XNCR) CEO Bassil Dahiyat on Q4 2021 Results - Earnings Call Transcript

Xencor, Inc. (XNCR) Q4 2021 Earnings Conference Call February 22, 2022, 17:00 ET Company Participants Charles Liles - Associate Director and Head, Corporate Communications & IR Bassil Dahiyat - Co-Founder, CEO, President & Director Allen Yang - SVP & Chief Medical Officer John Kuc...

XNCR - Xencor GAAP EPS of $1.21 beats by $1.11, revenue of $154.02M beats by $77.73M

Xencor press release (NASDAQ:XNCR): Q4 GAAP EPS of $1.21 beats by $1.11. Revenue of $154.02M (+268.0% Y/Y) beats by $77.73M. The company expects to have cash to fund research and development programs and operations through the end of 2025. Xencor expects to end 2022 with between $500M and $55...

XNCR - Xencor Reports Fourth Quarter and Full Year 2021 Financial Results

-- Management to Host Conference Call at 4:30 p.m. ET Today -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported financial results for the four...
XNCR - Notable earnings after Wednesday's close

AAN, ACA, OTCPK:ACLLF, AEM, AEVA, AGI, AHT, ALLO, ALR, AMED, ANSS, ARNA, AZUL, BAND, BBDC, BBWI, BCSF, BHP, BIRD, BKNG, BMA, BMRN, CCRN, CDEV, CHDN, CHK, CLOV, CMLS, CPE, CSV, CTRA, CW, DHC, DK, DKL, EBAY, EFC, OTCPK:EIFZF, EVH, EXR, FBRT, FIVN, FIX, FLGT, FLS, FNF, FRG, FTI, FUBO, GBT, GH, G...

XNCR - Xencor to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on February 23, 2022

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today announced that it will provide a corporate update and report financial results for th...

XNCR - Xencor Highlights 2022 Corporate Priorities and Portfolio Milestones

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced 2022 corporate priorities and anticipated clinical development and research milestones. ...
Previous 10 Next 10